Year-two follow-up results of an observational study conducted in Crohn's disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting

被引：0
|
作者：
Laharie, D. [1 ]
Pierron, G. [2 ]
Brault, Y. [3 ]
Bouhnik, Y. [4 ]
Nancey, S. [5 ,6 ]
机构：
[1] Univ Hosp Ctr Bordeaux, Dept Gastroenterol, Bordeaux, France
[2] Pfizer, Inflammat & Immunol, Paris, France
[3] Pfizer, Stat, Paris, France
[4] Paris IBD Ctr, Grp Hosp Prive Ambroise Pare Hartmann, Neuilly Sur Seine, France
[5] Lyon South Hosp Pierre Benite, Lyon, France
[6] INSERM, U1111 CIRI, Dept Gastroenterol, Lyon, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P529
引用
收藏
页码：658 / 659
页数：2
相关论文
共 50 条
  • [21] DRUG SURVIVAL AND IMMUNOGENICITY AFTER SWITCHING FROM REMICADE® TO BIOSIMILAR CT-P13 IN INFLAMMATORY BOWEL DISEASE PATIENTS: TWO YEAR FOLLOW-UP OF A PROSPECTIVE OBSERVATIONAL COHORT STUDY
    Smits, Lisa
    Derikx, Lauranne
    van Esch, Aura
    Drenth, Joost
    Boshuizen, Ronald
    De Jong, Dirk J.
    Hoentjen, Frank
    GASTROENTEROLOGY, 2018, 154 (06) : S822 - S822
  • [22] BIOSIMILAR INFLIXIMAB (CT-P13) IS NOT INFERIOR TO ORIGINATOR INFLIXIMAB: EXPLORATIVE IBD SUBGROUP-ANALYSES IN CROHN'S DISEASE AND ULCERATIVE COLITIS FROM THE NOR-SWITCH TRIAL
    Joergensen, Kristin K.
    Olsen, Inge C.
    Goll, Guro L.
    Lorentzen, Merete
    Bolstad, Nils
    Berset, Ingrid P.
    Haavardsholm, Espen A.
    Lundin, Knut E.
    Mork, Cato
    Kvien, Tore K.
    Jahnsen, Jorgen
    GASTROENTEROLOGY, 2017, 152 (05) : S65 - S66
  • [23] Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
    Jorgensen, K. K.
    Olsen, I. C.
    Goll, G. L.
    Lorentzen, M.
    Bolstad, N.
    Berset, I. P.
    Haavardsholm, E. A.
    Lundin, K. E.
    Mork, C.
    Kvien, T. K.
    Jahnsen, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S62 - S63
  • [24] Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
    F. Argüelles-Arias
    M. F. Guerra Veloz
    R. Perea Amarillo
    A. Vilches-Arenas
    L. Castro Laria
    B. Maldonado Pérez
    D. Chaaro
    A. Benítez Roldán
    V. Merino
    G. Ramírez
    A. Caunedo Álvarez
    M. Romero Gómez
    Digestive Diseases and Sciences, 2017, 62 : 1305 - 1312
  • [25] Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
    Argulles-Arias, F.
    Guerra Veloz, M. F.
    Perea Amarillo, R.
    Vilches-Arenas, A.
    Castro Laria, L.
    Maldonado Perez, B.
    Chaaro, D.
    Benitez Roldan, A.
    Merino, V.
    Ramirez, G.
    Caunedo Alvarez, A.
    Romero-Gomez, Manuel
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (05) : 1305 - 1312
  • [26] Drug survival and immunogenicity after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: Two-year follow-up of a prospective observational cohort study
    Smits, L.
    Derikx, L.
    van Esch, A.
    Drenth, J.
    Boshuizen, R.
    de Jong, D.
    Hoentjen, F.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S353 - S353
  • [27] Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study
    Smits, Lisa J. T.
    van Esch, Aura A. J.
    Derikx, Lauranne A. A. P.
    Boshuizen, Ronald
    de Jong, Dirk J.
    Drenth, Joost P. H.
    Hoentjen, Frank
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (01) : 172 - 179
  • [28] Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers
    Tursi, Antonio
    Mocci, Giammarco
    Faggiani, Roberto
    Allegretta, Leonardo
    Della Valle, Nicola
    Forti, Giacomo
    Franceschi, Marilisa
    Ferronato, Antonio
    Gallina, Sara
    Larussa, Tiziana
    Luzza, Francesco
    Lorenzetti, Roberto
    Penna, Antonio
    Rodino, Stefano
    Sebkova, Ladislava
    Lauria, Angelo
    Piergallini, Simona
    Pranzo, Giuseppe
    Ricciardelli, Cristina
    Zampaletta, Costantino
    Elisei, Walter
    Picchio, Marcello
    ANNALS OF GASTROENTEROLOGY, 2019, 32 (04): : 392 - 399
  • [29] UNCHANGED INFLIXIMAB SERUM CONCENTRATIONS AFTER SWITCHING FROM THE ORIGINATOR INFLIXIMAB TO THE BIOSIMILAR CT-P13 IN PATIENTS WITH QUIESCENT CROHN'S DISEASE: A PROSPECTIVE STUDY
    Strik, Anne S.
    van de Vrie, W.
    Megen, Yvonne
    Minekus, Joanne
    Rispens, Theo
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2017, 152 (05) : S66 - S66
  • [30] Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
    Strik, A.
    van de Vrie, W.
    van Megen, Y.
    Bloemsaat-Minekus, J.
    Rispens, T.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S420 - S420
12345